Sugi Predict

Sugi Predict / Compounds / SCHEMBL1318237

SCHEMBL1318237

SCHEMBL1318237

CC(C)c1nc(Cl)cc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.37
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ GABRA1 P14867 1/20 0.32
▸ GABRB1 P18505 1/20 0.32
▸ ESR1 P03372 1/20 0.31
▸ HAVCR2 Q8TDQ0 1/20 0.31
▸ GLP1R P43220 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ ACHE P22303 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ S1PR2 O95136 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1586144 0.85 LMNA (0.42) LMNAALDH1A1TP53CYP3A4TSHR
SCHEMBL10167708 0.85 NOS3 (0.38) LMNACYP2C19ALDH1A1CYP3A4TSHR
SCHEMBL4471413 0.84 LMNA (0.33) LMNA
SCHEMBL4586148 0.84 NOS2 (0.41) LMNAALDH1A1
Hydrochloric Acid SCHEMBL11087162 0.82 GABRA1 (0.34) LMNAGABRA1GABRB1
SCHEMBL10851033 0.82 SMN1; SMN2 (0.36) LMNAGABRA1GABRB1
SCHEMBL19564465 0.80 KMT2A (0.42) LMNACYP1A2CYP2C9CYP2C19TSHR
SCHEMBL5321863 0.80 SMN1; SMN2 (0.40) LMNACYP1A2ALDH1A1TP53CYP3A4
SCHEMBL20578770 0.80 HRH4 (0.33) LMNAHSD17B10
SCHEMBL24738607 0.79 S1PR2 (0.32) LMNAGABRA1GABRB1S1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 — — WO disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
EP-4337198-A1 POLO LIKE KINASE 4 INHIBITORS Oric Pharmaceuticals, Inc. (US) 2024-03-20 — — EP disclosed
WO-2024035950-A1 INHIBITORS OF KIF18A AND USES THEREOF ACCENT THERAPEUTICS, INC. (US) 2024-02-15 — — WO disclosed
EP-1456201-A1 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-15 — — EP disclosed
WO-2004041164-A2 KINASE INHIBITORS MERCK & CO., INC. (US) 2004-05-21 — — WO disclosed
WO-2003053957-A1 BENZHYDRYL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (US) 2003-07-03 — — WO disclosed
EP-0565488-B1 Fluorine free titanocenes and their application CIBA GEIGY AG (CH) 1999-04-21 — — EP disclosed
US-5340701-A Photoinitiators CIBA-GEIGY CORPORATION (US) 1994-08-23 — — US disclosed
EP-0565488-A1 Fluorine free titanocenes and their application CIBA-GEIGY AG (CH) 1993-10-13 — — EP disclosed
EP-0055214-B1 2-ALKYL-5-ALKYLSULFONYL-4,6-DIHALOGEN PYRIMIDINES AND PROCESS FOR THEIR PREPARATION CIBA-GEIGY AG (CH) 1985-05-22 — — EP disclosed
US-4413124-A 2-Alkyl-5-alkylsulfonyl-4,6-dihalopyrimidines and the production thereof CIBA-GEIGY CORPORATION (US) 1983-11-01 — — US disclosed
US-4412074-A 2-Alkyl-5-alkyl sulfony 1-4,6-dihalopyrimidines and the production thereof CIBA-GEIGY CORPORATION (US) 1983-10-25 — — US disclosed
EP-0055214-A1 2-Alkyl-5-alkylsulfonyl-4,6-dihalogen pyrimidines and process for their preparation CIBA-GEIGY AG (CH) 1982-06-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN LMNA 273/4885CYP1A2 19/4885CYP2C9 40/4885
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 LMNA 2193/4885CYP1A2 3631/4885CYP2C9 2604/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 LMNA 2193/4885CYP1A2 3631/4885CYP2C9 2604/4885
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP LMNA 2914/4885CYP1A2 3527/4885CYP2C9 4193/4885
US-20260062416-A1 INHIBITORS OF KIF18A AND USES THEREOF KIF18A, KIF18B, KIF5B LMNA 1439/4885CYP1A2 3183/4885CYP2C9 4371/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 LMNA 2199/4885CYP1A2 3573/4885CYP2C9 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.